Crohn's Disease: Current Pathogenetic Paradigms

Mucosal Immunology, Two-Volume Set

Volumn , Issue , 2005, Pages 1265-1285

  Duchmann, Rainer ^a   Zeitz, Martin ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84857053142     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012491543-5/50076-0     Document Type: Chapter

References (183)

1. Ajuebor M.N., Swain M.G. Role of chemokines and chemokine receptors in the gastrointestinal tract. Immunology 2002, 105(2):137-143.
2. Aluwihare A.P. Electron microscopy in Crohn's disease. Gut 1971, 12(7):509-518.
3. Andus T., Rogler G., Daig R., Falk W., Schölmerich J., Gross V. The role of macrophages. Inflammatory Bowel Diseases 1995, 197-281. Kluwer, Lancaster.
4. Arihiro S., Ohtani H., Suzuki M., Murata M., Ejima C., Oki M., et al. Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn's disease. Pathol. Int. 2002, 52(5-6):367-374.
5. Atreya R., Mudter J., Finotto S., Mullberg J., Jostock T., Wirtz S., et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat. Med. 2000, 6(5):583-588.
6. Baklien K., Brandtzaeg P. Comparative mapping of the local distribution of immunoglobulin-containing cells in ulcerative colitis and Crohn's disease of the colon. Clin. Exp. Immunol. 1975, 22(2):197-209.
7. Baklien K., Brandtzaeg P. Immunohistochemical characterization of local immunoglobulin formation in Crohn's disease of the ileum. Scand. J. Gastroenterol. 1976, 11(5):447-457.
8. Berg R.D. The indigenous gastrointestinal microflora. Trends Microbiol. 1996, 4(11):430-435.
9. Binder V. Progress in epidemiology, quality of life and life expectancy in IBD. Inflammatory Bowel Diseases 1995, 27-31. Kluwer, Lancaster.
10. Binder V., Hendriksen C., Kreiner S. Prognosis in Crohn's disease-based on results from a regional patient group from the county of Copenhagen. Gut 1985, 26(2):146-150.
11. Binion D.G., West G.A., Volk E.E., Drazba J.A., Ziats N.P., Petras R.E., et al. Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet 1998, 352(9142):1742-1746.
12. Boirivant M., Marini M., Di Felice G., Pronio A.M., Montesani C., Tersigni R., et al. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 1999, 116(3):557-565.
13. Bonen D.K., Cho J.H. The genetics of inflammatory bowel disease. Gastroenterology 2003, 124(2):521-536.
14. Breslin N., Nash C., Hilsden R., Hershfield N., Price L., Meddings J., et al. Intestinal permeability is increased in a proportion of spouses of patients with Crohn's disease. Am. J. Gastroenterol 2001, 96(10):2934-2938.
15. Buisine M.P., Desreumaux P., Leteurtre E., Copin M.C., Colombel J.F., Porchet N., et al. Mucin gene expression in intestinal epithelial cells in Crohn's disease. Gut 2001, 49(4):544-551.
16. Burgio V.L., Fais S., Boirivant M., Perrone A., Pallone F. Peripheral monocyte and naive T-cell recruitment and activation in Crohn's disease. Gastroenterology 1995, 109(4):1029-1038.
17. Cario E., Podolsky D.K. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect. Immun. 2000, 68(12):7010-7017.
18. Chao L.P., Steele J., Rodrigues C., Lennard-Jones J., Stanford J.L., Spiliadis C., et al. Specificity of antibodies secreted by hybridomas generated from activated B cells in the mesenteric lymph nodes of patients with inflammatory bowel disease. Gut 1988, 29(1):35-40.
19. Chiodini R.J., Van Kruiningen H.J., Thayer W.R., Merkal R.S., Coutu J.A. Possible role of mycobacteria in inflammatory bowel disease. I. An unclassified Mycobacterium species isolated from patients with Crohn's disease. Dig. Dis. Sci. 1984, 29(12):1073-1079.
20. Chiodini R.J. Inflammatory Bowel Diseases 1995, 9-21. Kluwer, Lancaster.
21. Chiodini R.F. Inflammatory Bowel Diseases 1995, 437-450. Kluwer, Lancaster.
22. + T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J. Exp. Med. 1998, 187(6):855-864.
23. Cong Y., Weaver C.T., Lazenby A., Elson C.O. Bacterialreactive T regulatory cells inhibit pathogenic immune responses to the enteric flora. J. Immunol. 2002, 169(11):6112-6119.
24. Choy M.Y., Walker-Smith J.A., Williams C.B., MacDonald T.T. Differential expression of CD25 (interleukin-2 receptor) on lamina propria T cells and macrophages in the intestinal lesions in Crohn's disease and ulcerative colitis. Gut 1990, 31(12):1365-1370.
25. Dalwadi H., Wei B., Kronenberg M., Sutton C.L., Braun J. The Crohn's disease-associated bacterial protein 12 is a novel enteric T cell superantigen. Immunity 2001, 15(1):149-158.
26. Dalziel D.K. Chronic interstitial enteritis. BMJ 1913, 2:1068-1070.
27. D'Haens G.R., Geboes K., Peeters M., Baert F., Penninckx F., Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998, 114(2):262-267.
28. Deem R.L., Targan S.R., Niederlehner A., Shanahan F. The CD8+ Leu-7+ subset of T cells in Crohn's disease: distinction between cytotoxic and covert suppressor functions. Clin. Exp. Immunol. 1990, 80(3):387-394.
29. Duchmann R., Neurath M.F., Meyer zum Buschenfelde K.H. Responses to self and non-self intestinal microflora in health and inflammatory bowel disease. Res. Immunol. 1997, 148(8-9):589-594.
30. Duchmann R., May E., Heike M., Knolle P., Neurath M., Meyer zum Buschenfelde K.H. T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans. Gut 1999, 44(6):812-818.
31. Duchmann R., Schmitt E., Knolle P., Meyer zum Buschenfelde K.H., Neurath M. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur. J. Immunol. 1996, 26(4):934-938.
32. Duchmann R., Kaiser I., Hermann E., Mayet W., Ewe K., Meyer zum Buschenfelde K.H. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin. Exp. Immunol. 1995, 102(3):448-455.
33. Duchmann R. Consequences of the modulation of luminal bacterial antigens for the intestinal immune response. Mechanisms of intestinal inflammation 2004, Kluwer Academic, Philadelphia.
34. Farmer R.G., Hawk W.A., Turnbull R.B. Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology 1975, 68(4):627-635. Pt 1.
35. Fellermann K., Ludwig D., Stahl M., David-Walek T., Stange E.F. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am. J. Gastroenterol. 1998, 93(10):1860-1866.
36. Fiocchi C., Battisto J.R., Farmer R.G. Studies on isolated gut mucosal lymphocytes in inflammatory bowel disease. Detection of activated T cells and enhanced proliferation to Staphylococcus aureus and lipopolysaccharides. Dig. Dis. Sci. 1981, 26(8):728-736.
37. Fiocchi C., Roche J.K., Michener W.M. High prevalence of antibodies to intestinal epithelial antigens in patients with inflammatory bowel disease and their relatives. Ann. Intern. Med. 1989, 110(10):786-794.
38. Foo M.C., Lee A. Antigenic cross-reaction between mouse intestine and a member of the autochthonous microflora. Infect. Immun. 1974, 9(6):1066-1069.
39. Fuss I.J., Neurath M., Boirivant M., Klein J.S., de la Motte C., Strong S.A., et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 1996, 157(3):1261-1270.
40. Gasche C., Scholmerich J., Brynskov J., D'Haens G., Hanauer S.B., Irvine E.J., et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm. Bowel Dis. 2000, 6(1):8-15.
41. Gaston J.S. Pathogenic role of gut inflammation in the spondyloarthropathies. Curr. Opin. Rheumatol. 1997, 9(4):302-307.
42. Gent A., Hellier M., Grace R., Swarbrick E., Coggon D. Inflammatory bowel disease and domestic hygiene in infancy. Lancet 1994, 343:766-767.
43. Gazzard B.G., Price H.L., Libby G.W., Dawson A.M. The social toll of Crohn's disease. Br. Med. J. 1978, 2(6145):1117-1119.
44. Ghosh S., Goldin E., Gordon F.H., Malchow H.A., Rask-Madsen J., Rutgeerts P., et al. Natalizumab for active Crohn's disease. N. Engl. J. Med. 2003, 348(1):24-32.
45. Giaffer M.H., Holdsworth C.D., Duerden B.I. Virulence properties of Escherichia coli strains isolated from patients with inflammatory bowel disease. Gut 1992, 33(5):646-650.
46. Gitter A.H., Bendfeldt K., Schulzke J.D., Fromm M. Leaks in the epithelial barrier caused by spontaneous and TNF-alpha-induced single-cell apoptosis. Faseb J. 2000, 14(12):1749-1753.
47. Glasser A.L., Boudeau J., Barnich N., Perruchot M.H., Colombel J.F., Darfeuille-Michaud A. Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. Infect. Immun. 2001, 69(9):5529-5537.
48. Greenstein A.J., Lachman P., Sachar D.B., Springhorn J., Heimann T., Janowitz H.D., et al. Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. Gut 1988, 29(5):588-592.
49. Greenstein A.J., Janowitz H.D., Sachar D.B. The extraintestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976, 55(5):401-412.
50. Gulwani-Akolkar B., Akolkar P.N., Minassian A., Pergolizzi R., McKinley M., Mullin G., et al. Selective expansion of specific T cell receptors in the inflamed colon of Crohn's disease. J. Clin. Invest. 1996, 98(6):1344-1354.
51. Hampe J., Grebe J., Nikolaus S., Solberg C., Croucher P., Mascheretti S., et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 2002, 359:16661-16665.
52. Hermiston M.L., Gordon J.I. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 1995, 270(5239):1203-1207.
53. Hesterberg P.E., Winsor-Hines D., Briskin M.J., Soler-Ferran D., Merrill C., Mackay C.R., et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology 1996, 111(5):1373-1380.
54. Hilsden R.J., Meddings J.B., Sutherland L.R. Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease. Gastroenterology 1996, 110(5):1395-1403.
55. Hisamatsu T., Suzuki M., Reinecker H.C., Nadeau W.J., McCormick B.A., Podolsky D.K. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003, 124(4):993-1000.
56. Hoffmann J.C., Zeitz M. Standard therapy of Crohn disease. Consensus-based recommendations. Internist (Berl) 2002, 43(11):1376.
57. Hoffmann J.C., Zeitz M. Standard therapy of Crohn disease. Consensus-based recommendations. Internist (Berl) 2002, 43(11):1379-1385.
58. Hollander D., Vadheim C.M., Brettholz E., Petersen G.M., Delahunty T., Rotter J.I. Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann. Intern. Med. 1986, 105(6):883-885.
59. Holtmeier W., Hennemann A., May E., Duchmann R., Caspary W.F. T cell receptor delta repertoire in inflamed and noninflamed colon of patients with IBD analyzed by CDR3 spectratyping. Am. J. Physiol. Gastrointest. Liver Phyxiol. 2002, 282(6):G1024-G1034.
60. Hommes D., van den Blink B., Plasse T., Bartelsman J., Xu C., Macpherson B., et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002, 122(1):7-14.
61. Hugot J.P., Laurent-Puig P., Gower-Rousseau C., Olson J.M., Lee J.C., Beaugerie L., et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996, 379(6568):821-823.
62. Ibbotson J.P., Lowes J.R., Chahal H., Gaston J.S., Life P., Kumararatne D.S., et al. Mucosal cell-mediated immunity to mycobacterial, enterobacterial and other microbial antigens in inflammatory bowel disease. Clin. Exp. Immunol. 1992, 87(2):224-230.
63. Ina K., Itoh J., Fukushima K., Kusugami K., Yamaguchi T., Kyokane K., et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J. Immunol. 1999, 163(2):1081-1090.
64. Inohara N., Ogura Y., Nunez G. Nods: a family of cytosolic proteins that regulate the host response to pathogens. Curr. Opin. microbiol. 2002, 5(1):76-80.
65. Inohara N.Y.O., Fontalba A., Gutierrez O., Pons F., Crespo J., et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J. Biol. Chem. 2003, 278:5509-5512.
66. Iwasaki A., Kelsall B.L. Mucosal immunity and inflammation. I. Mucosal dendritic cells: their specialized role in initiating T cell responses. Am. J. Physiol. 1999, 276(5):G1074-G1078. Pt 1.
67. James S.P., Fiocchi C., Graeff A.S., Strober W. Phenotypic analysis of lamina propria lymphocytes. Predominance of helper-inducer and cytolytic T-cell phenotypes and deficiency of suppressor-inducer phenotypes in Crohn's disease and control patients. Gastroenterology 1986, 91(6):1483-1489.
68. James S.P., Neckers L.M., Graeff A.S., Cossman J., Balch C.M., Strober W. Suppression of immunoglobulin synthesis by lymphocyte subpopulations in patients with Crohn's disease. Gastroenterology 1984, 86(6):1510-1518.
69. Kald B., Olaison G., Sjodahl R., Tagesson C. Novel aspect of Crohn's disease: increased content of platelet-activating factor in ileal and colonic mucosa. Digestion 1990, 46(4):199-204.
70. Keighley M.R., Arabi Y., Dimock F., Burdon D.W., Allan R.N., Alexander-Williams J. Influence of inflammatory bowel disease on intestinal microflora. Gut 1978, 19(12):1099-1104.
71. Kett K., Rognum T.O., Brandtzaeg P. Mucosal subclass distribution of immunoglobulin G-producing cells is different in ulcerative colitis and Crohn's disease of the colon. Gastroenterology 1987, 93(5):919-924.
72. Khoo U.Y., Proctor I.E., Macpherson A.J. CD4+ T cell down-regulation in human intestinal mucosa: evidence for intestinal tolerance to luminal bacterial antigens. J. Immunol. 1997, 158(8):3626-3634.
73. Koizumi M., King N., Lobb R., Benjamin C., Podolsky D.K. Expression of vascular adhesion molecules in inflammatory bowel disease. Gastroenterology 1992, 103(3):840-847.
74. Kontiainen S., Scheinin T., Halme L. Number of activated T-helper cells and NK cells in peripheral blood is decreased in severe Crohn's disease. Apmis 1996, 104(5):355-361.
75. Landers C.J., Cohavy O., Misra R., Yang H., Lin Y.C., Braun J., et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 2002, 123(3):689-699.
76. Lennard J.J. Classification of inflammatory bowel disease. Scand. J. Gastroenterol. Suppl. 1989, 170:2-6.
77. Lindberg E., Soderholm J.D., Olaison G., Tysk C., Jarnerot G. Intestinal permeability to polyethylene glycols in monozygotic twins with Crohn's disease. Scand. J. Gastroenterol. 1995, 30(8):780-783.
78. Liu Y., van Kruiningen H.J., West A.B., Cartun R.W., Cortot A., Colombel J.F. Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology 1995, 108(5):1396-1404.
79. Loftus E.V. A matter of life or death: mortality in Crohn's disease. Inflamm. Bowel Dis. 2002, 8(6):428-429.
80. Ludviksson B.R., Gray B., Strober W., Ehrhardt R.O. Dysregulated intrathymic development in the IL-2-deficient mouse leads to colitis-inducing thymocytes. J. Immunol. 1997, 158(1):104-111.
81. Lugering A., Schmidt M., Lugering N., Pauels H.G., Domschke W., Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspas-dependent pathway. Gastroenterology 2001, 121(5):1145-1157.
82. MacDermott R.P., Nahm M.H. Expression of human immunoglobulin G subclasses in inflammatory bowel disease. Gastroenterology 1987, 93(5):1127-1129.
83. MacDermott R.P., Bragdon M.J., Kodner I.J., Bertovich M.J. Deficient cell-mediated cytotoxicity and hyporesponsiveness to interferon and mitogenic lectin activation by inflammatory bowel disease peripheral blood and intestinal mononuclear cells. Gastroenterology 1986, 90(1):6-11.
84. MacDermott R.P., Nash G.S., Bertovich M.J., Mohrman R.F., Kodner I.J., Delacroix D.L., et al. Altered patterns of secretion of monomeric IgA and IgA subclass 1 by intestinal mononuclear cells in inflammatory bowel disease. Gastroenterology 1986, 91(2):379-385.
85. Macpherson A., Khoo U.Y., Forgacs I., Philpott-Howard J., Bjarnason I. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996, 38(3):365-375.
86. Malchow H., Ewe K., Brandes J.W., Goebell H., Ehms H., Sommer H., et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984, 86(2):249-266.
87. Mantyh C.R., Gates T.S., Zimmerman R.P., Welton M.L., Passaro E.P., Vigna S.R., et al. Receptor binding sites for substance P, but not substance K or neuromedin K, are expressed in high concentrations by arterioles, venules, and lymph nodules in surgical specimens obtained from patients with ulcerative colitis and Crohn disease. Proc. Natl. Acad. Sci. USA 1988, 85:3235-3239. (9).
88. Mantyh C.R., Vigna S.R., Bollinger R.R., Manthy P.W., Maggio J.E., Pappas T.N. Differential expression of substance P receptors in patients with Crohn's disease and ulcerative colitis. Gastroenterology 1995, 109(3):850-860.
89. Marth T., Strober W., Kelsall B.L. High dose oral tolerance in ovalbumin TCR-transgenic mice: systemic neutralization of IL-12 augments TGF-beta secretion and T cell apoptosis. J. Immunol. 1996, 157(6):2348-2357.
90. Matson A.P., Van Kruiningen H.J., West A.B., Cartun R.W., Colombel J.F., Cortot A. The relationship of granulomas to blood vessels in intestinal Crohn's disease. Mod. Pathol. 1995, 8(6):680-685.
91. May E., Lambert C., Holtmeier W., Hennemann A., Zeitz M., Duchmann R. Regional variation of the alphabeta T cell repertoire in the colon of healthy individuals and patients with Crohn's disease. Hum. Immunol. 2002, 63(6):467-480.
92. May E., Marker-Hermann E., Wittig B.M., Zeitz M., Meyer zum Buschenfelde K.H., Duchmann R. Identical T-cell expansions in the colon mucosa and the synovium of a patient with enterogenic spondyloarthropathy. Gastroenterology 2000, 119(6):1745-1755.
93. Mayer L., Eisenhardt D. Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease. J. Clin. Invest. 1990, 86(4):1255-1260.
94. Medzhitov R., Janeway C. Innate immunity. N. Engl. J. Med. 2000, 343(5):338-344.
95. Mee A.S., McLaughlin J.E., Hodgson H.J., Jewell D.P. Chronic immune colitis in rabbits. Gut 1979, 20(1):1-5.
96. Mekhjian H.S., Switz D.M., Melnyk C.S., Rankin G.B., Brooks R.K. Clinical features and natural history of Crohn's disease. Gastroenterology 1979, 77(4):898-906. Pt 2.
97. Meyers S., Janowitz H.D. "Natural history" of Crohn's disease. An analytic review of the placebo lesson. Gastroenterology 1984, 87(5):1189-1192.
98. Monteleone G., MacDonald T.T., Wathen N.C., Pallone F., Pender S.L. Enhancing Lamina propria Th1 cell responses with interleukin 12 produces severe tissue injury. Gastroenterology 1999, 117(5):1069-1077.
99. Monteleone G., Trapasso F., Parrello T., Biancone L., Stella A., Iuliano R., et al. Bioactive IL-18 expression is upregulated in Crohn's disease. J. Immunol. 1999, 163(1):143-147.
100. Moss M.T., Sanderson J.D., Tizard M.L., Hermon-Taylor J., el-Zaatari F.A., Markesich D.C., et al. Polymerase chain reaction detection of Mycobacterium paratuberculosis and Mycobacterium avium subsp silvaticum in long term cultures from Crohn's disease and control tissues. Gut 1992, 33(9):1209-1213.
101. Mottet C., Uhlig H.H., Powrie F. Cutting edge: cure of colitis by CD4+CD25+regulatory T cells. J. Immunol. 2003, 170(8):3939-3943.
102. Mowat A.M. The regulation of immune responses to dietary protein antigens. Immunol. Today 1997, 8:93-98.
103. Mullin G., Maycon Z., Sampat A., Vezza F., Braun-Elwert L., Duchmann R., Weissman G., Katz S., McKinley M., James S., Fischer S. Intestinal mucosal lymphokine production in Crohn's disease has a Th1 profile. Gastroenterology 1993, 104.
104. Nakajima A., Kodama T., Yazaki Y., Takazoe M., Saito N., Suzuki R., et al. Specific clonal T cell accumulation in intestinal lesions of Crohn's disease. J. Immunol. 1996, 157(12):5683-5688.
105. Neurath M.F., Fuss I., Kelsall B.L., Presky D.H., Waegell W., Strober W. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J. Exp. Med. 1996, 183(6):2605-2616.
106. Neurath M.F., Weigmann B., Finotto S., Glickman J., Nieuwenhuis E., Iijima H., et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J. Exp. Med. 2002, 195(9):1129-1143.
107. Neurath M.F., Fuss I., Kelsall B.L., Stuber E., Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 1995, 182(5):1281-1290.
108. Neurath M.F., Pettersson S., Meyer zum Buschenfelde K.H., Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat. Med. 1996, 2(9):998-1004.
109. Nielsen O.H., Langholz E., Hendel J., Brynskov J. Circulating soluble intercellular adhesion molecule-1 (sICAM-1) in active inflammatory bowel disease. Dig. Dis. Sci. 1994, 39(9):1918-1923.
110. Olaison G., Smedh K., Sjodahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 1992, 33(3):331-335.
111. Pallone F., Fais S., Squarcia O., Biancone L., Pozzilli P., Boirivant M. Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease. In vivo state of activation and in vitro response to stimulation as defined by the expression of early activation antigens. Gut 1987, 28(6):745-753.
112. Parronchi P., Romagnani P., Annunziato F., Sampognaro S., Becchio A., Giannarini L., et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am. J. Pathol. 1997, 150(3):823-832.
113. Pavli P., Maxwell L., Van de Pol E., Doe F. Distribution of human colonic dendritic cells and macrophages. Clin. Exp. Immunol. 1996, 104(1):124-132.
114. Pirzer U., Schonhaar A., Fleischer B., Hermann E., Meyer zum Buschenfelde K.H. Reactivity of infiltrating T lymphocytes with microbial antigens in Crohn's disease. Lancett 1991, 338(8777):1238-1239.
115. Pirzer U.C., Schurmann G., Post S., Betzler M., Meuer S.C. Differential responsiveness to CD3-Ti vs. CD2-dependent activation of human intestinal T lymphocytes. Eur. J. Immunol. 1990, 20(10):2339-2342.
116. Podolsky D.K., Isselbacher K.J. Composition of human colonic mucin. Selective alteration in inflammatory bowel disease. J. Clin. Invest. 1983, 72(1):142-153.
117. Powrie F., Leach M.W., Mauze S., Menon S., Caddle L.B., Coffman R.L. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994, 1(7):553-562.
118. Probert C.S., Chott A., Turner J.R., Saubermann L.J., Stevens A.C., Bodinaku K., et al. Persistent clonal expansions of peripheral blood CD4+ lymphocytes in chronic inflammatory bowel disease. J. Immunol. 1996, 157(7):3183-3191.
119. Qiao L., Schurmann G., Betzler M., Meuer S.C. Activation and signaling status of human lamina propria T lymphocytes. Gastroenterology 1991, 101(6):1529-1536.
120. Qiao L., Golling M., Autschbach F., Schurmann G., Meuer S.C. T cell receptor repertoire and mitotic responses of lamina propria T lymphocytes in inflammatory bowel disease. Clin. Exp. Immunol. 1994, 97(2):303-308.
121. Reinshagen M., Rohm H., Steinkamp M., Lieb K., Geerling I., Von Herbay A., et al. Protective role of neurotrophins in experimental inflammation of the rat gut. Gastroenterology 2000, 119(2):368-376.
122. Rescigno M., Urbano M., Valzasina B., Francolini M., Rotta G., Bonasio R., et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immunol. 2001, 2(4):361-367.
123. Robertson D., Sandler R. Measles virus and Crohn's disease: a critical appraisal of the current literature. Inflamm. Bowel Dis. 2001, 7(1):51-57.
124. Roman L.I., Manzano L., De La Hera A., Abreu L., Rossi I., Alvarez-Mon M. Expanded CD4+CD45RO+ phenotype and defective proliferative response in T lymphocytes from patients with Crohn's disease. Gastroenterology 1996, 110(4):1008-1019.
125. Rosenstiel P., Fantini M., Brautigam K., Kuhbacher T., Waetzig G.H., Seegert D., et al. TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD 15) gene in human intestinal epithelial cells. Gastroenterology 2003, 124(4):1001-1009.
126. Ruseler-van Embden J.G., Both-Patoir H.C. Anaerobic gramnegative faecal flora in patients with Crohn's disease and healthy subjects. Antonie Van Leeuwenhoek 1983, 49(2):125-132.
127. Rutgeerts P., Geboes K., Vantrappen G., Beyls J., Kerremans R., Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990, 99(4):956-963.
128. Rutgeerts P., Goboes K., Peeters M., Hiele M., Penninckx F., Aerts R., et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991, 338(8770):771-774.
129. Sachar D.B., Andrews H.A., Farmer R.G., Pallone F., Pena A.S., Prantera C., Rutgeerts P. Proposed classification of patient subgroups in Crohn's disease. Gastroenterol. Int. 1992, 5:141-154.
130. Sandborn W.J., Targan S.R. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002, 122(6):1592-1608.
131. Sankey E.A., Dhillon A.P., Anthony A., Wakefield A.J., Sim R., More L., et al. Early mucosal changes in Crohn's disease. Gut 1993, 34(3):375-381.
132. Sartor R.B. Role of the intestinal microflora in pathogenesis and complications. Inflammatory Bowel Disease: Pathophysiology as Basis of Treatment 1992, Kluwer, Lancaster.
133. Sartor R.B., Cromartie W.J., Powell D.W., Schwab J.H. Granulomatous enterocolitis induced in rats by purified bacterial cell wall fragments. Gastroenterology 1985, 89(3):587-595.
134. Saubermann L.J., Probert C.S., Christ A.D., Chott A., Turner J.R., Stevens A.C., et al. Evidence of T cell receptor betachain patterns in inflammatory and noninflammatory bowel disease states. Am. J. Physiol. 1999, 276(3):G613-G621. Pt 1.
135. Saverymuttu S.H., Peters A.M., Lavender J.P., Chadwick V.S., Hodgson H.J. In vivo assessment of granulocyte migration to diseased bowel in Crohn's disease. Gut 1985, 26(4):378-383.
136. Schmitz-Moorman P., Becker H. Histologic studies on the formal pathogenesis of the epithelial cell granuloma in Crohn's disease. Recent Advances in Crohn's Disease 1991, Martinus Nijhoff, The Hague.
137. Schreiber S., MacDermott R.P., Raedler A., Pinnau R., Bertovich M.J., Nash G.S. Increased activation of isolated intestinal lamina propria mononuclear cells in inflammatory bowel disease. Gastroenterology 1991, 101(4):1020-1030.
138. Schurmann G.M., Bishop A.E., Facer P., Vecchio M., Lee J.C., Rampton D.S., et al. Increased expression of cell adhesion molecule P-selectin in active inflammatory bowel disease. Gut. 1995, 36(3):411-418.
139. Seibold F., Weber P., Scheurlen M. Autoantibodies in IBD patients and their families. Inflammatory Bowel Diseases 1995, Kluwer, Lancaster.
140. Selby W.S., Janossy G., Bofill M., Jewell D.P. Intestinal lymphocyte subpopulations in inflammatory bowel disease: an analysis by immunohistological and cell isolation techniques. Gut 1984, 25(1):32-40.
141. Sido B., Braunstein J., Breitkreutz R., Herfarth C., Meuer S.C. Thiol-mediated redox regulation of intestinal lamina propria T lymphocytes. J. Exp. Med. 2000, 192(6):907-912.
142. Siegmund B., Fantuzzi G., Rieder F., Gamboni-Robertson F., Lehr H.A., Hartmann G., et al. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001, 281(4):R1264-R1273.
143. Silverstein M.D., Loftus E.V., Sandborn W.J., Tremaine W.J., Feagan B.G., Nietert P.J., et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999, 117(1):49-57.
144. Sorensen V.Z., Olsen B.G., Binder V. Life prospects and quality of life in patients with Crohn's disease. Gut 1987, 28(4):382-385.
145. Stallmach A., Wittig B.M., Moser C., Fischinger J., Duchmann R., Zeitz M. Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease. Gut 2003, 52(3):377-382.
146. Stallmach A., Giese T., Pfister K., Wittig B.M., Kunne S., Humphries M., et al. Activation of beta(1) integrins mediates proliferation and inhibits apoptosis of intestinal CD4-positive lymphocytes. Eur. J. Immunol. 2001, 31(4):1228-1238.
147. Strober W., Fuss I.J., Blumberg R.S. The immunology of mucosal models of inflammation. Annu. Rev. Immunol. 2002, 20:495-549.
148. Summers R.W., Switz D.M., Sessions J.T., Becktel J.M., Best W.R., Kern F., et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979, 77(4):847-869. Pt 2.
149. Swidsinski A., Ladhoff A., Pernthaler A., Swidsinski S., Loening-Baucke V., Ortner M., et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002, 122(1):44-54.
150. Swift G.L. Antimycobacterial trials in Crohn's disease. Inflammatory Bowel Disease 1995, Kluwer, Lancaster.
151. Tanaka M., Riddell R.H. The pathological diagnosis and differential diagnosis of Crohn's disease. Hepatogastroenterology 1990, 37(1):18-31.
152. Targan S.R., Deem R.L., Liu M., Wang S., Nel A. Definition of a lamina propria T cell responsive state. Enhanced cytokine responsiveness of T cells stimulated through the CD2 pathway. J. Immunol. 1995, 154(2):664-675.
153. ten Hove T., van Montfrans C., Peppelenbosch M.P., van Deventer S.J. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002, 50(2):206-211.
154. teVelde A.A., van Kooyk Y., Braat H., Hommes D.W., Dellemijn T.A., Slors J.F., et al. Increased expression of DC-SIGN+IL-12+IL-18+ and CD83+IL-12-IL-18-dendritic cell populations in the colonic mucosa of patients with Crohn's disease. Eur. J. Immunol. 2003, 33(1):143-151.
155. Thomas G.A., Rhodes J., Green J.T. Inflammatory bowel disease and smoking-a review. Am. J. Gastroenterol. 1998, 93(2):144-149.
156. Tiede I., Fritz G., Strand S., Poppe D., Dvorsky R., Strand D., et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest. 2003, 111(8):1133-1145.
157. Tilg H., van Montfrans C., van den Ende A., Kaser A., van Deventer S.J., Schreiber S., et al. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut 2002, 50(2):191-195.
158. Toivanen P., Vaahtovuo J., Eerola E. Influence of major histocompatibility complex on bacterial composition of fecal flora. Infect. Immun. 2001, 69(4):2372-2377.
159. Toy L.S., Yio X.Y., Lin A., Honig S., Mayer L. Defective expression of gp180, a novel CD8 ligand on intestinal epithelial cells, in inflammatory bowel disease. J. Clin. Invest. 1997, 100(8):2062-2071.
160. Tysk C., Lindberg E., Jarnerot G., Floderus-Myrhed B. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988, 29(7):990-996.
161. Tysk C., Riedesel H., Lindberg E., Panzini B., Podolsky D., Jarnerot G. Colonic glycoproteins in monozygotic twins with inflammatory bowel disease. Gastroenterology 1991, 100(2):419-423.
162. Van de Merwe J.P., Stegeman J.H., Hazenberg M.P. The resident faecal flora is determined by genetic characteristics of the host. Implications for Crohn's disease?. Antonie Van Leeuwenhoek 1983, 49(2):119-124.
163. Van de Merwe J.P., Schroder A.M., Wensinck F., Hazenberg M.P. The obligate anaerobic faecal flora of patients with Crohn's disease and their first-degree relatives. Scand. J. Gastroenterol. 1988, 23(9):1125-1131.
164. van der Waaij L.A., Kroese F.G.M., Jansen P.L.M., Visser A., Hunter J.O. Anaerobic bacteria in feces of patients with IBD are coated with
165. Wehkamp J., Fellermann K., Herrlinger K.R., Baxmann S., Schmidt K., Schwind B., et al. Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 2002, 14(7):745-752.
166. Wehkamp J., Schwind B., Herrlinger K.R., Baxmann S., Schmidt K., Duchrow M., et al. Innate immunity and colonic inflammation: enhanced expression of epithelial alpha-defensins. Dig. Dis. Sci. 2002, 47(6):1349-1355.
167. Wakefield A.J., Sawyerr A.M., Dhillon A.P., Pittilo R.M., Rowles P.M., Lewis A.A., et al. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet 1989, 2(8671):1057-1062.
168. Weiner H.L. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol. Today 1997, 18(7):335-343.
169. Weldon M.J., Masoomi A.M., Britten A.J., Gane J., Finlayson C.J., Joseph A.E., et al. Quantification of inflammatory bowel disease activity using technetium-99m HMPAO labelled leucocyte single photon emission computerised tomography (SPECT). Gut 1995, 36(2):243-250.
170. Wijesinha S.S., Steer H.W. Studies of the immunoglobulin-producing cells of the human intestine: the defunctioned bowel. Gut 1982, 23(3):211-214.
171. Wirtz S., Finotto S., Kanzler S., Lohse A.W., Blessing M., Lehr H.A., et al. Chronic intestinal inflammation in STAT-4 transgenic mice: characterization of disease and adoptive transfer by TNF-plus IFN-gamma-producing CD4+ T cells that respond to bacterial antigens. J. Immunol. 1999, 162(4):1884-1888.
172. Wittig B., Schwarzler C., Fohr N., Gunthert U., Zoller M. Curative treatment of an experimentally induced colitis by a CD44 variant V7-specific antibody. J. Immunol. 1998, 161(3):1069-1073.
173. Wittig B., Seiter S., Schmidt D.S., Zuber M., Neurath M., Zoller M. CD44 variant isoforms on blood leukocytes in chronic inflammatory bowel disease and other systemic autoimmune diseases. Lab Invest. 1999, 79:747-759.
174. Wittig B.M., Johansson B., Zoller M., Schwarzler C., Gunthert U. Abrogation of experimental colitis correlates with increased apoptosis in mice deficient for CD44 variant exon 7 (CD44v7). J. Exp. Med. 2000, 191(12):2053-2064.
175. Wright N.A., Poulsom R., Stamp G., Van Noorden S., Sarraf C., Elia G., et al. Trefoil peptide gene expression in gastrointestinal epithelial cells in inflammatory bowel disease. Gastroenterology 1993, 104(1):12-20.
176. Wyatt J., Vogelsang H., Hubl W., Waldhoer T., Lochs H. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993, 341(8858):1437-1439.
177. Wirtz S., Becker C., Blumberg R., Galle P.R., Neurath M.F. Treatment of T cell-dependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA. J. Immunol. 2002, 168(1):411-420.
178. Yacyshyn B.R., Chey W.Y., Goff J., Salzberg B., Baerg R., Buchman A.L., et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002, 51(1):30-36.
179. Yio X.Y., Mayer L. Characterization of a 180-kDa intestinal epithelial cell membrane glycoprotein, gp180. A candidate molecule mediating T cell-epithelial cell interactions. J. Biol. Chem. 1997, 272(19):12786-12792.
180. Zeitz M., Schieferdecker H.L., Ullrich R., Jahn H.U., James S.P., Riecken E.O. Phenotype and function of lamina propria T lymphocytes. Immunol. Res. 1991, 10(3-4):199-206.
181. Zeitz M., Greene W.C., Peffer N.J., James S.P. Lymphocytes isolated from the intestinal lamina propria of normal nonhuman primates have increased expression of genes associated with T-cell activation. Gastroenterology 1988, 94(3):647-655.
182. Zeitz M., Quinn T.C., Graeff A.S., James S.P. Mucosal T cells provide helper function but do not proliferate when stimulated by specific antigen in lymphogranuloma venereum proctitis in nonhuman primates. Gastroenterology 1988, 94(2):353-366.
183. Zeitz M., Quinn T.C., Graeff A.S., Schwarting R., James S.P. Oral administration of cyclosporin does not prevent expansion of antigen-specific, gut-associated, and spleen lymphocyte populations during Chlamydia trachomatis proctitis in nonhuman primates. Dig. Dis. Sci. 1989, 34(4):585-595.